Merrimack Pharma (MACK) Tops Q2 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Mizuho Securities Reiterates Bullish Stance on Merrimack Pharmaceuticals (MACK) Into MM-398 PDUFA Date
August 11, 2015 7:46 AM EDTMizuho Securities analyst Peter Lawson reiterated an Outperform rating and $16 price target on Merrimack Pharmaceuticals (NASDAQ: MACK) heading into an October 24 PDUFA date for MM-398.
"The company remains one of our favorite biotech plays and we feel it is overlooked by investors, given... More
